SJ

Shah Jayeshkumar Revabhai

Active Director Director DIN 08474521
DIN 08474521 First appointment Jun 2019 Primary industry Veterinary
Unlock full profile Investments Β· shareholding Β· contact details
Current companies 1 active board seats
Total affiliations 1 Since Jun 2019
Shareholding value β€’β€’β€’β€’ Premium profile

About Shah Jayeshkumar Revabhai

Data last updated:

Shah Jayeshkumar Revabhai is a Director at Irja Pharma Foundation (since 2019). The company operates in Veterinary.

DIN 08474521
Primary Designation Director
Industry Veterinary
First Appointment 19 Jun 2019
Oldest Company Age 7 yrs

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Irja Pharma Foundation U85200GJ2019NPL108735
Director19 Jun 20192019Active

Board colleagues of Shah Jayeshkumar Revabhai

Directorship timeline

Open interactive timeline →
Irja Pharma Foundation
Premium access

Shareholding and investment profile for Shah Jayeshkumar Revabhai

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Shah Jayeshkumar Revabhai

Shah Jayeshkumar Revabhai currently holds 1 directorship: Irja Pharma Foundation (Director, since 19 Jun 2019).

Shah Jayeshkumar Revabhai was first appointed on 19 Jun 2019 as Director at Irja Pharma Foundation.

The current boards of Shah Jayeshkumar Revabhai's companies include Harshadkumar Bhikhabhai Solanki (Irja Pharma Foundation), Parmar Pareshkumar Viththalbhai (Irja Pharma Foundation), Prakash Fulabhai Solanki (Irja Pharma Foundation), Yogesh Parshottambhai Varma (Irja Pharma Foundation).

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available